| Active Not Recruiting | First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer NCT05189457 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Ask Questions (ASQ):Implementation of a Communication Intervention NCT05025748 | Barbara Ann Karmanos Cancer Institute | N/A |
| Unknown | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites NCT04267575 | Jerome Canady, M.D. | N/A |
| Completed | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT03805594 | University of California, San Francisco | Phase 1 |
| Recruiting | Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostat NCT03880422 | Roswell Park Cancer Institute | N/A |
| Terminated | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Canc NCT03827473 | University of Utah | Phase 2 |
| Withdrawn | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants Wi NCT03477864 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Active Not Recruiting | Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prosta NCT03344211 | University of Southern California | Phase 2 |
| Completed | Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bon NCT03707184 | University of Utah | Phase 2 |
| Unknown | Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer NCT04113096 | The University of The West Indies | EARLY_Phase 1 |
| Active Not Recruiting | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer NCT03511196 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Withdrawn | Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resis NCT03596710 | Jonsson Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer NCT02881242 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partn NCT03112668 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer NCT03016741 | Northwestern University | Phase 4 |
| Unknown | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Can NCT02935205 | Mamta Parikh | Phase 1 / Phase 2 |
| Active Not Recruiting | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration- NCT03012321 | Northwestern University | Phase 2 |
| Completed | Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate C NCT03123978 | Mamta Parikh | Phase 1 |
| Terminated | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies NCT02985021 | Seattle Institute for Biomedical and Clinical Research | Phase 2 |
| Active Not Recruiting | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer NCT02807805 | Mamta Parikh | Phase 2 |
| Terminated | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer NCT02516670 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containin NCT02598895 | University of Washington | Phase 2 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer NCT02489357 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Withdrawn | Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With NCT02169063 | University of Washington | N/A |
| Completed | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer NCT02278185 | University of Colorado, Denver | Phase 2 |
| Unknown | Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer NCT02615223 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Terminated | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant P NCT02491411 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer NCT02499835 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Completed | Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery NCT02144649 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer NCT02048150 | City of Hope Medical Center | Phase 1 |
| Completed | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cance NCT02159950 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Ca NCT02206334 | NRG Oncology | Phase 1 |
| Completed | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer NCT02184533 | Stanford University | Phase 1 |
| Completed | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate C NCT02058706 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine NCT01992016 | University of Colorado, Denver | N/A |
| Active Not Recruiting | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prosta NCT02023463 | Thomas Jefferson University | Phase 1 |
| Unknown | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metasta NCT01949337 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Under NCT01912820 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer NCT02012296 | University of Chicago | Phase 1 / Phase 2 |
| Terminated | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01866423 | University of Southern California | Phase 2 |
| Completed | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer NCT01881867 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer NCT01848067 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery NCT02603965 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel- NCT01833208 | Roswell Park Cancer Institute | N/A |
| Terminated | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cance NCT01913015 | OHSU Knight Cancer Institute | Phase 1 |
| Terminated | Cabozantinib in Men With Castration-Resistant Prostate Cancer NCT01703065 | University of Washington | Phase 2 |
| Completed | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate NCT01807065 | City of Hope Medical Center | Phase 2 |
| Completed | Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients NCT02050906 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer NCT01731912 | University of Washington | N/A |
| Completed | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant NCT02228265 | OHSU Knight Cancer Institute | — |
| Completed | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer NCT01812668 | Barbara Ann Karmanos Cancer Institute | N/A |
| Unknown | Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resi NCT01685125 | University of Southern California | Phase 2 |
| Terminated | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated NCT01469338 | University of Southern California | Phase 2 |
| Completed | Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostat NCT01599793 | University of Chicago | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivati NCT01555632 | University of Nebraska | N/A |
| Completed | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resis NCT01498978 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer NCT01533246 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer NCT01174199 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Tivantinib in Treating Patients With Metastatic Prostate Cancer NCT01519414 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer NCT01543776 | University of Chicago | Phase 2 |
| Completed | Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer NCT01385059 | City of Hope Medical Center | Phase 2 |
| Completed | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01468532 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Completed | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Tre NCT01270880 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Saracatinib in Treating Patients With Prostate Cancer NCT01267266 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly D NCT01120236 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Ca NCT01240629 | University of Southern California | Phase 1 / Phase 2 |
| Terminated | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer NCT01200810 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistan NCT01145508 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer NCT01117935 | Virginia Commonwealth University | N/A |
| Completed | Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients NCT00956163 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Completed | Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer NCT01023061 | University of Washington | Phase 2 |
| Completed | Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer NCT01050842 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer NCT01026623 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen NCT01682941 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients Wit NCT00936975 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients NCT00879619 | John P. Fruehauf | Phase 1 / Phase 2 |
| Completed | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Can NCT00666666 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate NCT00937768 | Mayo Clinic | Phase 2 |
| Terminated | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That D NCT00527124 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy NCT00337077 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate NCT00536991 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy NCT00331344 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer NCT00330161 | National Cancer Institute (NCI) | Phase 2 |
| Completed | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel NCT00096499 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Re NCT00110214 | National Cancer Institute (NCI) | Phase 3 |
| Completed | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy NCT00118092 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cilengitide in Treating Patients With Metastatic Prostate Cancer NCT00103337 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer NCT00095667 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Metastatic Prostate Cancer NCT00087139 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer NCT00170157 | Mayo Clinic | Phase 2 |
| Completed | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-S NCT00074022 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Perifosine in Treating Patients With Recurrent Prostate Cancer NCT00058214 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate NCT00058084 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00058253 | National Cancer Institute (NCI) | Phase 1 |
| Completed | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy NCT00040755 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer NCT00039104 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer NCT00016107 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) NCT00005039 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer NCT00020046 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer NCT00019695 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer NCT00003534 | Burzynski Research Institute | Phase 2 |
| Withdrawn | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer NCT00003517 | Burzynski Research Institute | Phase 2 |